Rockwell Medical, Inc. Hits New 52-Week High of $5.69

Rockwell Medical, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 5.69 on July 1, 2026. This achievement marks a remarkable increase in the stock's performance, with a one-year gain of 175.33%, significantly outpacing the S&P 500's performance of 20.74% over the same period. The company's market capitalization stands at USD 34 million, reflecting its microcap status. Despite its recent stock performance, Rockwell Medical is currently operating at a loss, as indicated by its price-to-earnings ratio, which is not applicable. The company has a price-to-book ratio of 0.93, suggesting that its stock may be undervalued relative to its assets. Additionally, Rockwell Medical's debt-to-equity ratio is reported at -0.39, indicating a unique financial structure. However, the company does not offer a dividend yield, which is consistent with many firms in the biotechnology space that reinvest earnings into research and development. The stock's previous 52-week low was recorded at USD 0.55, highlighting the significant upward movement in its price.